- Home
- NVMI vs EXEL Comparison
NVMI vs EXEL Comparison
Compare NVMI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVMI | EXEL |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 11.1B |
| IPO Year | 2000 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NVMI | EXEL |
|---|---|---|
| Price | $456.34 | $44.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 23 |
| Target Price | ★ $372.14 | $45.45 |
| AVG Volume (30 Days) | 352.7K | ★ 2.2M |
| Earning Date | 02-12-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 44.31 | ★ 53.55 |
| EPS | ★ 7.71 | 2.38 |
| Revenue | $852,719,000.00 | ★ $2,288,218,000.00 |
| Revenue This Year | $33.32 | $9.74 |
| Revenue Next Year | $10.23 | $12.27 |
| P/E Ratio | $59.78 | ★ $18.63 |
| Revenue Growth | ★ 39.37 | 9.93 |
| 52 Week Low | $154.00 | $31.90 |
| 52 Week High | $475.00 | $49.62 |
Technical Indicators
Market Signals| Indicator | NVMI | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 78.00 | 52.18 |
| Support Level | $400.34 | $43.00 |
| Resistance Level | $475.00 | $45.41 |
| Average True Range (ATR) | 16.73 | 1.65 |
| MACD | 6.59 | -0.09 |
| Stochastic Oscillator | 85.81 | 58.22 |
Price Performance
Historical ComparisonAbout NVMI Nova Ltd.
Nova Ltd is a semiconductor equipment manufacturer. The company provides metrology solutions for process control used in semiconductor manufacturing. The company offers in-line optical and x-ray stand-alone metrology systems, as well as integrated optical metrology systems. The product range consists of Nova 2040, Nova 3090Next, Nova i500 and i500 Plus, Nova T500, Nova T600, Nova V2600, HelioSense 100, Nova Hybrid Metrology solution, NovaMars. The company generates the majority of its revenue from China. Geographically the company has its business spread across the region of Taiwan, Korea, China, the United States, and Europe.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.